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Abstract
Background and Purpose—To quantify uncertainties in scoring radiation pneumonitis.
Materials and Methods—Records of 434 patients irradiated for lung cancer from 2000–2010 
were retrospectively reviewed; IRB-approved study. From these, 121 received ≥60 Gy for non-
small cell lung cancer (NSCLC) with ≥6 months follow-up. Patients where the physicians were 
uncertain of the diagnosis due to confounding factors were deemed “hard to score”. Subgroups 
were defined based on lung dosimetric parameters, and frequencies in different subgroups were 
compared via Fisher’s exact test.
Results—21/121 of patients were considered to have pneumonitis; median follow 17 months. Of 
these, 10/21 were “hard to score”; reasons including acute COPD exacerbation, infection, and 
tumor progression. “Hard to score” pneumonitis was slightly more common in patients with a 
COPD history (15%) vs. without COPD (4%) (p=0.05); and with a pre-RT FEV1 < 1.7L (16%) vs. 
≥ 1.7L (4%) (p=0.09). Rates of “unambiguous” pneumonitis trended to be non-significantly 
slightly higher in patients higher mean lung doses, V5, and V30.
Conclusion—Radiation pneumonitis occurred in 17% of patients undergoing RT for NSCLC; 
with diagnostic uncertainty in 48% of these. Poor pre-RT pulmonary function increases the rate of 
“hard to score” pneumonitis. Dosimetric parameters are slightly better related to “unambiguous” 
than “hard to score” pneumonitis, as expected.
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Introduction
Radiotherapy (RT) plays an important role in the treatment of lung cancer; primarily as 
definitive therapy with or without chemotherapy in patients with unresectable tumors. RT-
induced lung injury is a major dose limiting toxicity. Radiation pneumonitis, manifest 
primarily as shortness of breath, occurs in approximately 15–40% of patients within about 
1–6 months post-RT (1, 2).
Most studies reporting the rates of pneumonitis do not explicitly acknowledge the 
uncertainties in identifying and scoring pneumonitis. Kocak et al. (3) noted that the 
diagnosis of radiation pneumonitis was challenging in 28% of patients suspected of having 
radiation pneumonitis after RT for lung cancer, with uncertainties related to concurrent 
medical conditions (e.g. infection, cardiac disease, emphysema).
In order to reassess this issue, we herein perform an analysis of patients receiving thoracic 
RT for lung cancer to assess the incidence of radiation pneumonitis, and the frequency and 
causes of ambiguities in scoring radiation pneumonitis. Further, the impact of such 
ambiguous cases on the apparent relationship between dosimetric parameters and the 
incidence of radiation pneumonitis is assessed.
Methods and Materials
Patient population
As part of an Institutional Review Board-approved study, the records of 434 patients 
irradiated between 2000 and 2010 for lung cancer were reviewed. Patients were included in 
the analysis if they received thoracic RT for non small cell lung cancer (NSCLC) (with or 
without chemotherapy) with curative intent, and had a minimum received total dose ≥60 Gy. 
The majority of patients had squamous cell carcinoma (42%), NSCLC not otherwise 
specified (26%), and adenocarcinoma (21%). Patients who had surgery before and/or after 
RT were excluded. From the records reviewed, 155 patients were identified for inclusion in 
this analysis. The balance of cases was treated with palliative intent for local/distant disease, 
received <60 Gy, had small cell histology, or also had surgery. Only patients who had ≥ 6-
months follow-up (121 patients) were considered in the current analysis.
The medical records were reviewed to assess for the development of pulmonary symptoms 
(typically shortness of breath) consistent with radiation pneumonitis. Typically the diagnosis 
of radiation pneumonitis was noted in the medical record as a possible or likely cause of the 
patient’s symptoms.
The following grading system for pneumonitis, based on the modified National Cancer 
Institute Common Toxicity Criteria (CTC) was used: Grade 0, no increase in pulmonary 
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symptoms due to RT; Grade 1, increase in pulmonary symptoms not requiring initiation or 
increase in steroids and/or oxygen; Grade 2, RT-induced pulmonary symptoms requiring 
initiation or increase in steroids; Grade 3, RT-induced pulmonary symptoms requiring 
oxygen; and Grade 4, RT-induced pulmonary symptoms requiring intubation or causing 
death. Patients with radiologic changes reported as “RP” but without symptoms were not 
considered to have toxicity. The records of all patients with ≥grade 2 of pneumonitis were 
analyzed further.
Evaluation of symptomatic radiation pneumonitis
Each case was scored as either “unambiguous” or “hard to score” pneumonitis. A patient 
with “unambiguous” pneumonitis was one who presented with shortness of breath, with or 
without cough that responded to steroids and did not have any confounding clinical factors 
that might be the cause of their dyspnea (e.g. tumor progression, acute exacerbation of 
chronic obstructive pulmonary disease- COPD, infection and cardiac disease). The records 
from patients suspected of having radiation pneumonitis were reviewed by at least two 
physicians who reached a consensus opinion. Cases for which the physicians were uncertain 
of the diagnosis were deemed “hard to score” pneumonitis. These patients typically had 
clearly-recognized one or more clinical factors that confounded the diagnosis of radiation 
pneumonitis, the uncertainty was stated in the medical records and the therapeutic approach 
often addressed multiple etiologies of dyspnea (e.g. antibiotics given concurrently with 
steroids). Thus, patients in whom there were potential confounding factors (as would be the 
case with many of the patients, with, for example a prior history of COPD), but where the 
clinical record did not reflect any uncertainly, were not considered “hard to score”.
Treatment techniques
All patients were treated at University of North Carolina with 6 MV and/or 15 MV photon 
beams. Patients were generally treated with opposed anterior-posterior fields to 40–48 Gy, 
followed by off-cord fields to 60–90 Gy at 1.8–2.0 Gy per daily fraction. Four patients were 
treated using a hyperfractionated concurrent boost technique (1.25 Gy twice daily to the 
clinical target volume and 1.6 Gy twice daily to the gross disease to a total dose 60–86.4 Gy) 
and six patients were treated with split course technique (2.0–3.0 Gy per daily fraction with 
a break in the middle of treatment to a total dose 60–62.5 Gy).
Treatment planning and DVH parameters
The archived three dimension (3D) records between 2002 and 2010 were assessable in the 
97 patients. All these patients underwent computed tomography (CT) simulation and dose 
calculation using PLUNC (Plan University of North Carolina at Chapel Hill). The contours 
of the lung were reviewed and were adjusted to be relatively uniform among the patients. 
Both lungs were regarded as a single organ. Care was taken to exclude the gross tumor 
volume (GTV), trachea and bronchi from the anatomic lung used to compute the lung DVH 
used for the analyses. From the lung DVH, the following dosimetric variables were 
extracted: Mean lung dose (MLD) and the lung volume receiving ≥ a defined dose (Vdose); 
V5, V30. All doses were calculated to reflect tissue heterogeneity using a finite-size pencil 
beam algorithm with a Monte Carlo simulation result based 2-source model and a modified 
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Batho inhomogeneity correction. Patients were sorted into subgroups based on lung 
dosimetric parameters.
Statistical analysis
The patient and treatment characteristics, the rates of radiation pneumonitis (“unambiguous” 
vs. “hard to score” pneumonitis) were described by using simple descriptive statistics. The 
relation between possible confounding factors such as preexisting COPD history, low pre-
RT PFTs and rates of “hard to score” pneumonitis were analyzed with a 2 × 2 contingency 
table. Patients were divided into four quartiles based on quantitative data from dosimetric 
parameters (e.g. MLD, V5, and V30). The rates of radiation pneumonitis, (overall, “hard to 
score” and “unambiguous” pneumonitis) in patient subgroups were compared using Fisher’s 
exact test. All statistical tests were two-tailed and p≤0.05 was somewhat arbitrarily defined 
as statistically significant.
Results
Of the 121 patients, 21 patients (17%) were considered to possibly have Grade ≥2 radiation 
pneumonitis and were treated with steroids. The patient and treatment characteristics are 
shown in Tables 1 and 2.
Of these 21 patients, 11 patients had “unambiguous” pneumonitis, and 10 patients (48%) 
were deemed “hard to score”; reasons including acute exacerbation of COPD, infection and 
tumor progression, in 8, 5, and 3 patients, respectively (these numbers sum > 10 as some 
patients had multiple confounding factors). The patients with a possible acute COPD 
exacerbation usually had a prior exacerbation of COPD and the clinical notes clearly stated 
the uncertainty in diagnosis of pneumonitis. Six patients were treated with antibiotics 
concurrently with steroids.
The median follow up was 17 months (range, 6–108). Median time between completion of 
RT and onset of symptoms was 3 months for all pneumonitis, 4 months for “hard to score” 
pneumonitis, and 2 months for “unambiguous” pneumonitis.
Forty-eight patients had a pre-RT diagnosis of COPD; 10/48 (21%) were considered to have 
radiation pneumonitis; 7 “hard to score” and 3 “unambiguous”. In the 73 patients without 
COPD; 11/73 (15%) were considered to have RP; 3 “hard to score” and 8 “unambiguous”. 
Of the 118 patients who had PFTs available, 50 patients had a pre-RT FEV1 < 1.7L (cut-
point chosen as it was the population median value). In the 50 patients with a pre-RT FEV1 
< 1.7L; 13/50 (26%) were considered to have radiation pneumonitis; 5 “unambiguous” and 8 
“hard to score”. “Hard to score” pneumonitis was more common in patients with a history of 
COPD (15%) vs. without COPD (4%), p =0.05; and in those with a pre-RT FEV1 < 1.7L 
(16%) vs. ≥ 1.7L (4%), p=0.09.
In the 97 patients for whom the archived 3D records were assessable, the MLD ranged from 
8.8 to 35.3 Gy (mean 21.2 Gy), V5 ranged from 6.2 to 70.4% (mean 38.3%) and V30 ranged 
from 3.7 to 46.4% (mean 22.7%).
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The frequency of “unambiguous” and “hard to score” pneumonitis among patient quartile 
subgroups, based on MLD, V5 and V30, is shown in Table 3. The rates of “unambiguous” 
pneumonitis (but not to “hard to score” pneumonitis) trended to be non-significantly slightly 
higher in patients higher (vs. lower) MLD, V5 and V30 (p>0.05).
Discussion
There are no well established methods to qualitatively or quantitatively describe the 
certainty of a toxicity score. To our knowledge, the certainty with which radiation 
pneumonitis can be scored has not been formally evaluated. Kocak et al. noted that 28% of 
their patients with suspected radiation pneumonitis had confounding medical conditions 
(infection, cardiac disease, and emphysema), making the clinical diagnosis uncertain (3).
In the present study, approximately 48% of radiation pneumonitis cases were scored as 
“hard to score” due to confounding factors (e.g. tumor progression, acute exacerbation of 
COPD, and infection). “Hard to score” pneumonitis was more common in patients with pre-
existing lung disease; as assessed by a documented history of COPD or relatively low pre-
RT PFTs. The clinical presentation of radiation pneumonitis may mimic that of an 
exacerbation of preexisting lung disease (e.g. “COPD flare”) which may often be associated 
with infection (4).
Many individual studies, as well as the recent QUANTEC review, note that the risk of 
symptomatic radiation pneumonitis generally increases with increasing dose/volume 
parameters, such as MLD, V20 and V30 (5, 6, 7). However, these predictions are not ideal; 
there are no apparent “thresholds” for risk, and there are marked inter-study variations in the 
absolute rates of radiation pneumonitis. This might result from the use of a variety of 
scoring systems- some that rely solely on symptomatic endpoints (8) while others also 
include radiographic endpoints. Further, vague terms such as “mild, moderate, and severe” 
are sometimes used in the scoring system. As noted in the present study, attribution bias 
(ascribing the patient’s symptoms to the RT vs. other causes) can have a marked impact on 
the observed rate of radiation pneumonitis (by a factor of two in our analysis as half of the 
patients with radiation pneumonitis were ambiguous). Further, this ambiguity appears to 
impact on the ability to relate symptoms to dosimetric parameters. The rate of unambiguous 
radiation pneumonitis was better related to radiation dosimetric parameters than were the 
ambiguous cases. Prior analyses similarly noted that predictive models based on dosimetric 
parameters are better correlated with outcomes when patients with the poorest pre-RT 
pulmonary function tests are excluded (9, 10). Presently, the uncertainty in scoring radiation 
pneumonitis is not considered in most reports, and the existing scoring systems do not 
explicitly acknowledge the potential for such uncertainties. Additional confounding effects 
result from things such as dose calculation uncertainties particularly at the lung-soft tissue 
interfaces, day-to-day set up variations, and intra- and inter-fraction motion of thoracic 
structures. Given the many uncertainties in the precise cause of post-RT symptoms, it might 
also be reasonable to consider scoring “all-cause post-RT dyspnea”, accepting that an 
increased incidence of COPD exacerbations, or chest infections or episodes of cardiac 
failure may also be a radiation-associated.
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The current analysis has several limitations. First, the method used to identify patients who 
are “hard to score” is not perfect. Nevertheless, we included only cases where the clinical 
records clearly noted some diagnostic uncertainty, and this seems reasonable. This study 
was entirely retrospective. Methods for documentation and details of medications 
recommended for patients were inconsistent. Thus, the absolute rate of pneumonitis may 
have been understated if the application of steroids for dyspnea was not clearly documented. 
Similarly, the assignment of symptomatic patients in to the “unambiguous” vs. “hard to 
score” pneumonitis subgroups may have been inexact.
Second, the patients reported in the current study were treated over a long time interval (10 
years), during which there were different care providers involved. Nevertheless, the majority 
of the patients were treated by a stable group of multi-disciplinary clinicians.
Third, grading symptoms based on the use of medications (e.g., steroid use) introduces a 
potential bias as physicians who are more likely to prescribe steroids may note a higher rate 
of radiation pneumonitis. This however is a generic concern of all studies that use the 
commonly-applied grading systems.
Fourth, the confounding impact of chemotherapy on the risk of radiation pneumonitis was 
not systematically addressed. Clinical data from the RTOG suggests that the chemotherapy 
may enhance the risk of radiation-associated pulmonary injury, (11), but the data on this are 
conflicting (7). In the current study, the chemotherapy regimens (agents and doses) were not 
detailed, and thus its impact was not practical to consider.
Fifth, the small sample size and the retrospective nature of the review, limits the power of 
the statistical analysis. For example, since the follow-up regiment was inconsistent, and 
pneumonitis was not assessed for in a uniform manner, some pneumonitis events may not 
have been apparent from the medical records. Therefore, the reported incidence might 
understate the true incidence. This is a common problem with retrospective clinical studies. 
Prospective series including large number of patients with the diagnosis of radiation 
pneumonitis are challenging since the incidence of pneumonitis is not that high. A more 
systematic multi-institutional/cooperative group-based study may help to further clarify this 
issue.
Conclusion
Radiation pneumonitis occurred in 17% of our patients undergoing RT (+/− chemotherapy) 
for NSCLC. Of these, the diagnosis of radiation pneumonitis is somewhat uncertain in 48%. 
Recognition of these uncertainties is needed when reporting rates of radiation pneumonitis 
and when comparing data from multiple institutions. The presence of poor pre-treatment 
pulmonary functional status (e.g. COPD and low PFTs) may increase the expected fraction 
of patients who will have “hard to score” pneumonitis. Therefore, differences in the pre-RT 
pulmonary functional status may account for some of the inter-institutional differences in 
the reported rates of radiation pneumonitis. Lung dosimetric parameters are slightly better 
related to “unambiguous” pneumonitis than “hard to score” pneumonitis, as expected. Given 
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the retrospective nature of this review, and the many uncertainties, the results should be 
considered as hypothesis generating, and requires further clarification and study.
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Table 1
Treatment
All patients (n=121) RP patients (n=21)
“unambiguous” (n=11) “hard to score” (n=10)
Radiotherapy, dose/fraction (total dose)
 1.8–2.0 (60–90Gy) 111 10 9
 1.25–1.6 (60–86.4Gy) 4 - 1
 2.0–3.0 (60–62.5Gy) 6 1 -
Chemotherapy*
 Pre-RT 5 1 -
 Concurrent 10 - 2
 Combined 85 8 4
 No chemotherapy 20 2 4
Abbreviations: RP= radiation pneumonitis
*
One patient (without RP) was treated with post-RT chemotherapy.
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Table 2
Patient characteristics
All patients (n=121) RP patients (n=21)
“unambiguous” (n=11) “hard to score” (n= 10)
Mean age (range, years) 60 (39–86) 65 (42–85) 64 (47–85)
Gender (male) 76 (63%) 7 (33%) 6 (29%)
Stage
 I 8 (7%) - 3 (14%)
 II 8 (7%) 1 (5%) 3 (14%)
 III 105 (86%) 10 (48%) 4 (19%)
Smoking history* 109 (92%) 10 (48%) 9 (43%)
Ongoing smoking* 56 (47%) 2 (10%) 7 (33%)
Primary tumor location
 Upper lobe 91 (75%) 7 (33%) 8 (38%)
Middle and/or lower lobe 30 (25%) 4 (19%) 2 (95%)
COPD history 48 (40%) 3 (14%) 7 (33%)
Pre-FEV1 <1.7 L ** 50 (42%) 5 (24%) 8 (38%)
Abbreviations: RP= radiation pneumonitis
*
Available in the 119 patients.
**
Using 1.7 L as a cut-point (the median value in our patients). Available in the 118 patients
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